A team led by scientists at the Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections.
If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of new antibacterial therapies. The protein's unique ability to bind generally to antibodies also should make it a valuable tool for research and drug development.
"What Protein M does to antibodies represents a very clever trick of evolution," says Richard A. Lerner, MD, the Lita Annenberg Hazen Professor of Immunochemistry and Institute Professor at TSRI who led the research.
The new findings, which were achieved through collaboration among several laboratories at TSRI and elsewhere, are described in the February 7, 2014 issue of the journal Science.
The unexpected discovery originated from an effort to understand the origin of multiple myeloma, a B-cell carcinoma. Clonal B-cell proliferation, as well as lymphomas and myelomas, can result from chronic infections by organisms such as Escherichia coli (E. coli), Helicobacter pylori (H. pylori) and hepatitis C virus.
To better understand this process, the team investigated mycoplasma, a parasite that infects people chronically and is largely confined to the surface of cells. In a search for factors associated with long-term mycoplasma infection, Rajesh Grover, PhD, a senior staff scientist in the Lerner laboratory, tested samples of antibodies from multiple myeloma patients' blood against a variety of mycoplasma species. One of the proteins recognized by the antibodies was from Mycoplasma genitalium, which causes sexually transmitted infections in humans.
To the scientists' surprise, every antibody sample tested showed reactivity to this protein. But further tests made clear that these antibody reactions were not in response to mass infection with M. genitalium. Instead, the scientists found, the mysterious M. genitalium protein appeared to have evolved simply to bind to any antibody it encounters.
That presents a potentially major problem for the immune system. The antibody response is meant to combat invading pathogens with precisely targeted attacks, each selected from an enormous repertoire of hundreds of millions of distinct antibodies. In effect, the system is designed not to bind universally to any one target. If it did, then such a target could act as a universal decoy, potentially nullifying the entire antibody response.
The current research suggested that M. genitalium has evolved such a decoy. "It binds to every antibody genericallycapable of hijacking the entire diversity of antibody repertoirebut at the same time it blocks the specific interaction between that antibody and its intended biomolecular target," says Grover. The team decided to call it "Protein M."
To better how understand Protein M works, Xueyong Zhu, PhD, a staff scientist in the laboratory of Ian Wilson, DPhil, the Hansen Professor of Structural Biology and chair of the Department of Integrative Structural and Computational Biology at TSRI, and colleagues took a structural biology approach. Using X-ray crystallography and other techniques, including electron microscopy in the TSRI lab of assistant professor Andrew Ward, PhD, the team determined the protein's 3D atomic structure while the protein was bound to various human antibodies.
Compared to thousands of known structures in the Protein Data Bank, the worldwide structure database, Protein M appeared to be unique.
The data also revealed that Protein M binds to a small, unchanging"conserved"region at the outer tip of every antibody's antigen-binding arm. "It likely extends the other end of itself, like a tail, over the antibody's main antigen-binding region," Zhu says.
The team is now studying Protein M's function during M. genitalium infections. It seems likely that the oddball protein evolved to help M. genitalium cope with the immune response despite having one of the smallest bacterial genomes in nature. "It appears to represent an elegant evolutionary solution to the special problem that mycoplasma have in evading the adaptive immune system," says Grover. "The smallest parasitic bacteria on planet earth seems to have evolved the most sophisticated invading molecular machine."
If Protein M is confirmed as a universal decoy for antibodies, it will become a target for new drugs, which could make it easier to treat chronic, sometimes silent infections by M. genitalium and by any other microbes that have evolved a similar antibody-thwarting defense. Chronic infections can lead to a host of other problems, including inflammatory diseases and cancers.
In principle, Protein M also could be engineered to target specific groups of B cellsimmune cells that produce antibodies and express them on their surfaces. Thus, Protein M could deliver cell-killing toxins to cancerous B cells but not healthy ones, for example to treat certain lymphomas.
In the era of antibody-based drugs, the most immediate use of Protein M is likely to be as a tool for grabbing antibodies in test tubes and cell cultures, useful for the preparation of highly pure antibody for research and drug manufacturing. Other generic antibody-binding proteins have been put to use in this way, but so far it appears that none does the job quite as well as Protein M. "It may be the most useful antibody purification device ever found," says Lerner, who is already in talks with industry to commercialize the protein.
In addition to Lerner, Wilson, Grover and Zhu, authors of the study, "A Structurally Unique Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union," were TSRI's Travis Nieusma, Teresa Jones, Isabel Boreo, Amanda S. MacLeod, Adam Mark, Sherry Niessen, Helen J. Kim, Leopold Kong, Vaughn V. Smider, Daniel R. Salomon and Andrew B. Ward; Nacyra Assad-Garcia, Keehwan Kwon and John I. Glass of the J Craig Venter Research Institute in Rockville, MD; Marta Chesi of the Mayo Clinic Arizona; Diane F. Jelinek and Robert A. Kyle of the Mayo Clinic College of Medicine in Rochester, MN; and Richard B. Pyles of the University of Texas Medical Branch, Galveston, TX.
The study was funded in part by the National Institutes of Health (RO1 AI042266, R21 AI098057, R01 AG020686, K08 AR063729, RR017573, U19 AI06360).
Source: Scripps Research Institute